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Abstract
Background: Disease-linked missense mutations can alter a protein’s function with fatal consequences for the affected
individual. How a single amino acid substitution in a protein affects its properties, is difficult to study in the context of the
cellular proteome, because mutant proteins can often not be traced in cells due to the lack of mutation-specific detection
tools. Antibodies, however, with their exquisite epitope specificity permit the detection of single amino acid substitutions
but are not available for the vast majority of disease-causing mutant proteins. One of the most frequently missense-mutated
human genes is the LMNA gene coding for A-type lamins. Mutations in LMNA cause phenotypically heterogenous, mostly
autosomal-dominant inherited diseases, termed laminopathies. The molecular mechanisms underlying the phenotypic
heterogeneity of laminopathies, however, are not well understood. Hence, the goal of this study was the development of
monoclonal antibodies specific for disease-linked point-mutant A-type lamins.
Methodology/Principal Findings: Using two different approaches of antigen presentation, namely KLH-coupled peptides
and the display of a complete protein domain fused to the Hepatitis B virus capsid protein, we developed monoclonal
antibodies against two disease-associated lamin A/C mutants. Both antibodies display exquisite specificity for the respective
mutant proteins. We show that with the help of these novel antibodies it is now possible for the first time to study
specifically the properties of the mutant proteins in primary patient cells in the background of wild-type protein.
Conclusions: We report here the development of two point-mutant specific antibodies against A-type lamins. While
synthetic peptides may be the prime choice of antigen, our results show that a given target sequence may have to be
presented in alternative ways to ensure the induction of a mutant-specific immune response. Point-mutant specific
antibodies will represent valuable tools for basic and clinical research on a number of hereditary as well as acquired diseases
caused by dominant missense mutations.
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Introduction
Currently, the NCBI dbSNP database has annotated more than
25 million human single nucleotide polymorphisms (SNPs)
(http://www.ncbi.nlm.nih.gov/snp/), and it is these SNPs, which
are responsible for the phenotypic differences between human
individuals. Non-synonymous (ns) SNPs, which result in an amino
acid change in the encoded protein, or SNPs in gene regulatory
regions can be associated with genetic diseases or an altered
susceptibility to disease. A number of bioinformatic studies have
used evolutionary and structural approaches to predict the effect of
nsSNPs (or missense mutations) on protein structure and func-
tion (http://coot.embl.de/PolyPhen/ or http://mmb2.pcb.ub.es:
8080/PMut/) [1,2,3,4,5]. However, a direct experimental analysis
of the mutant protein in patient cells has proven very difficult in
cases, where the wild type and the mutant protein are present in
the same cell, such as in autosomal dominant inherited diseases,
largely because of the lack of tools, which specifically recognize the
mutant protein within the proteome context and which would
allow to study the effect of the SNP/mutation on the protein
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knowledge of how mutations change protein structure and
function - e.g. its enzymatic activity, sub-cellular localization, or
interactions with other proteins – and why and how this is linked
to a certain disease phenotype, is still limited to studies based on
the ectopic expression of a tagged, mutant protein in non-diseased
cells. Thus, we need better and highly specific research tools,
which allow to distinguish between the wild-type and mutant
protein. Monoclonal antibodies with their unrivalled specificity for
defined epitopes can fulfill these demands. Moreover, besides their
use in basic research for better understanding the molecular
mechanisms of the disease pathogenesis, monoclonal antibodies
can also be applied for the diagnosis and prognosis of diseases as
well as for therapeutic interventions. Hence, point-mutant specific
monoclonal antibodies may not only represent extremely powerful
research tools to study somatic and inherited genetic diseases, but
could also emerge as valuable medical tools in the future.
Laminopathies represent a group of rare human hereditary
diseases, which are caused by mutations in genes encoding
components of the nuclear lamina, including the A- and B-type
lamins as well as lamin-associated proteins, e.g. emerin, lamina
associated polypeptide (LAP) 2a, or lamin B receptor (LBR) [6,7].
Today, at least 13 distinct laminopathies are known, which display
heterogenous phenotypes and include skeletal and/or cardiac
muscle dystrophies (e.g. Emery-Dreifuss muscular dystrophy -
EDMD), lipodystrophies (e.g. Dunnigan-type familial partial
lipodystrophy - FPLD), peripheral neuropathies, and accelerated
ageing syndromes [6,8,9]. In the LMNA gene alone, which codes
for the A-type lamins A and C, more than 200 mutations,
predominantly inherited in an autosomal dominant fashion and in
most cases single point missense mutations, have been described.
Interestingly, these mutations are found in all exons with no
apparent hot-spot clusters (Leiden Open Variation Database
(http://www.dmd.nl/lmna_seqvar.html)). Lamin A and lamin C
share the first 566 amino acids and display the characteristic
intermediate filament protein tripartite structure with a short N-
terminal head domain, a central a-helical rod domain and a C-
terminal globular domain, which in case of lamin A/C includes an
Ig-like fold (Figure 1A) [10,11,12]. While there are no mutation
hot-spot regions apparent in the LMNA gene, missense mutations
affecting two residues, which are both located within the Ig-fold
domain, have been found in a relatively large percentage of
laminopathy patients: first, an exchange of arginine 453 by
tryptophan (R453W), which was detected in 16% of autosomal-
dominant (AD-) EDMD cases (corresponding to 11% of all
laminopathy cases), and second, the substitution of arginine 482 by
either tryptophan, glutamine, or leucine (R482W/Q/L), which is
responsible for more than 80% of FPLD cases (and 13% of all
laminopathy cases) [13].
During the last decade few genes have received as much
attention from the scientific community as the LMNA gene.
Originally thought to play solely a structural role in order to
maintain nuclear shape, A-type lamins have now emerged as
crucial players of several functions in the nucleus, ranging from
transcriptional control and the organization of heterochromatin to
the regulation of various cell signaling pathways [14]. Neverthe-
less, it remains largely elusive, how mutations in a ubiquitously
expressed gene can cause tissue restricted pathogenic phenotypes.
Several possible explanations have been suggested, including
changes in lamin A/C dependent signaling pathways [15,16],
increased sensitivity to mechanical stress [17], impaired differen-
tiation [18], or alterations in lamina-mediated gene expression
[19]; however, different mechanisms (or a combination thereof)
might be responsible depending on the type of affected tissue.
Alternatively, impaired tissue regeneration due to deregulated
adult stem cells may be responsible for some of the pathological
conditions seen in laminopathy patients [20]. Since the vast
majority of LMNA mutations are inherited in a dominant fashion,
resulting in the side-by-side expression of wild-type and mutant
lamin A/C, researchers so far had to rely on studies using either
knock-out, knock-in or transgenic animals, or using non-diseased
cells, in which a certain tagged lamin A/C mutant was ectopically
expressed. Interestingly, most studies were based on the ectopic
expression of mutant lamin A alone without concomitant
expression of the respective lamin C mutant. With the exception
of mutations in the lamin A-unique far C-terminus, such an
approach creates a cellular environment, which does not mirror
the ‘‘real’’ situation in patient cells, where both A-type lamins are
affected by a mutation in the LMNA gene. Furthermore, while
several Lmna mouse models mimic the phenotypes of laminopa-
thies, such phenotypes manifest themselves only under homozy-
gous conditions [21]. Thus, antibodies specifically recognizing
mutant lamin A/C proteins would be highly valuable research
tools to study the molecular mechanisms of laminopathies in
primary human patient cells and tissues.
In this work, we generated two mouse monoclonal antibodies,
which specifically detect disease associated lamin A/C mutants but
do not cross-react with the wild-type counterpart. We show that
the design of the antigen, by which a certain mutated amino acid is
displayed, can be crucial for the induction of a specific immune
response. While an R453W specific antibody was generated
against a synthetic peptide, a peptide antigen failed to elicit an
R482W mutant specific humoral immune response. Rather, the
presentation of tryptophan 482 in the context of the whole C-
terminal Ig-fold domain of lamin A/C led to the development of
an R482W specific antibody. The novel antibodies presented here,
whose specificity was evaluated by Western blotting, competition
experiments, immunoprecipitation, and immunofluorescence mi-
croscopy assays, can now be applied to selectively study features of
the mutant A-type lamins in primary patient cells.
Materials and Methods
Ethics Statement
The maintenance of mice and experimental procedures have
been conducted according to the Austrian Animal Experiments
Act and have been approved by the Austrian Federal Ministry of
Science and Research (GZ 66.009/101-BrGT/2005 and GZ
66.009/61-C/GT/2007) and the animal experiments ethics
committee of the Medical University of Vienna. For the primary
human skin fibroblasts written informed consent was provided by
the patients for the investigation, sample and data management
under a protocol (BB53/07) approved August 03, 2007 by the
University of Greifswald ethics board according to the principles
expressed in the Declaration of Helsinki.
Cloning of expression constructs
The HBcAg cDNA for the HBcAg-Lamin A/C Ig-fold
expression plasmids was derived from the HBcAg-GFP expression
vector, pET28a-c149GFP (a gift from Michael Nassal, Freiburg).
pET28a-c149GFP was cut with NcoI/KpnI resulting in a
fragment coding for the N-terminus (aa1–78) of HBcAg followed
by a flexible glycine-rich linker (amino acid sequence:
GGGGSGGGGT). This N-terminal fragment of HBcAg was
inserted together with a new multiple cloning site (annealed oligos
MCS_fw and MCS_rev; containing the following restriction sites:
SnaBI, SphI, BsrGI, HindIII) into the bacterial expression vector
pB’His-NP cut with NcoI/SphI to give pB’His-HBcAg-Nterm.
Point Mutant Specific Antibody
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(amino acid sequence: GGGGSGGGG) followed by the C-
terminus of HBcAg (aa81–149) was cut from pET28a-c149GFP
with BsrGI/HindIII and cloned into pB’His-HBcAg-Nterm to
give pB’His-HBcAg-linker. The coding sequence of the wild-type,
the R453W, and the R482W mutant lamin A/C Ig-folds was
amplified by PCR from the respective pSVK3-LaminA plasmids
[22] with primers Igfold_fw and Igfold_rev. The PCR products
were cut with KpnI/BsrGI and cloned into pB’His-HBcAg-linker
to give pB’His-HBcAg-Ig-fold wt, pB’His-HBcAg-Ig-fold R453W,
and pB’His-HBcAg-Ig-fold R482W.
pB’His-HBcAg-Lamin A 478–487 R482W was cloned by
inserting the annealed oligos 478–487 R482W_fw and 478–487
R482W_rev into pB’His-HBcAg-linker. pB’His-HBcAg-Lamin A
472–492 R482W was cloned by inserting the annealed oligos 472–
492 R482W_fw and 472–492 R482W_rev into pB’His-HBcAg-
linker (both were inserted via KpnI/BsrGI). The coding sequence
for aa 458–503, or 438–523 was amplified by PCR from pB’His-
HBcAg-Ig-fold R482W with the primers 458_fw and 503_rev, or
438_fw and 523_rev, respectively, and inserted into pB’His-
HBcAg-linker via KpnI/BsrGI. The oligonucleotide sequences are
depicted in Table 1. The sequence of all expression constructs was
confirmed by sequencing.
Expression and purification of recombinant His-HBcAg
Ig-fold fusion proteins
6xHis-tagged recombinant proteins were expressed in the
bacterial strain Rosetta(DE3)pLysS (Novagen). Expression was
induced with 1mM IPTG for 3.5 hours at 37uC or room
temperature (RT). The bacterial cells were lysed by sonication
(3630 sec with 20 sec breaks between the sonication steps) on ice
in 25 mM Tris pH 8.4 containing PMSF and aprotinin. The
6xHis-tagged proteins were purified from the soluble fraction of
the lysate by incubation with Ni-NTA Agarose beads (Qiagen) o/n
Figure 1. Schematic presentation of lamin A/C and the HBcAg-Ig-fold fusion protein. (A) Tripartite structure of Lamin A and Lamin C
consisting of an N-terminal head domain, a long central alpha-helical rod domain, and a globular C-terminal Ig-fold domain. Lamin A contains a CaaX
signal motif for post-translational processing at its C-terminus. The two asterisks highlight the two mutations within the Ig-fold domain, R453W and
R482W, respectively, which were chosen as antigens. The amino acid sequences comprising the respective mutant amino acids are highlighted. (B)
Structure of the lamin A/C Ig-fold. The NMR structure obtained from Krimm et al. [11] was modified with the PyMOL Molecular Viewer program. The
position and the side chains of the amino acids Arg453 and Arg482 are highlighted in red, and the first and the last amino acid of the Ig-fold (Ser428
and Val549, respectively) are indicated. (C) Structure of HBcAg. The crystal structure obtained from Wynne et al. [50] was modified with the PyMOL
Molecular Viewer program. The immunodominant B-cell epitope c/e1 is highlighted in purple. (D) Recombinant HBcAg-Ig-fold protein. The Ig-fold,
either in the wild-type sequence or with the R453W or R482W point mutation (indicated by an asterisk) was cloned into the c/e1 epitope of the His-
HBcAg protein (aa 1–149), substituting amino acids Pro79 and Ala80. The Ig-fold is flanked by flexible glycine-rich linkers to allow proper folding of
the inserted Ig-fold as well as of the HBcAg protein.
doi:10.1371/journal.pone.0010604.g001
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PMSF and aprotinin) and 5x with washing buffer (50 mM
NaH2PO4; 300 mM NaCl; 20 mM imidazole, pH 8.0, PMSF,
aprotinin). Proteins were eluted with elution buffer (50 mM
NaH2PO4; 300 mM NaCl; 250 mM imidazole, pH 8.0, PMSF,
aprotinin) for 1 hour at 4uC or RT.
Peptides. The following keyhole limpet hemocyanin (KLH)-
coupled peptides (purchased from piCHEM, Graz, Austria) were
used for immunizations: R453W: Ac-
449GKFVWLRNK
457-C-
NH2; R482W: Ac-C-
478LLTYWFPPK
486-NH2).
Immunization of mice and fusion of splenocytes with
myeloma cells
50 mg of antigen per mouse and immunization were mixed with
adjuvant at a ratio of 1:1 and injected subcutaneously. After three
to four immunizations, a final boost of 50 mg of antigen without
adjuvant was injected into the tail vein. Four days after the final
immunization the splenocytes were fused with the myeloma cell
line X63Ag8.653 according to standard protocols using polyeth-
ylene glycol [23]. Hybridoma supernatants were screened for the
presence of antibodies by Western blotting after 7 days. Positive
single clones were obtained by limited dilution of mixed
hybridoma clones.
Cell lines
To generate cell lines stably expressing Flag-tagged lamin A wt/
R453W/R482W, HeLa cells (ATCC No. CCL-2; www.atcc.org)
were co-transfected with pSVK3-Flag-LaminA wt/R453W/
R482W and pTK-Hyg (Clontech; conferring hygromycin B
resistance) at a ratio of about 15:1 using lipofectamine 2000
(Invitrogen) according to the manufacturer’s guidelines. Stably
expressing cells were selected in the presence of 175 mg/ml of
Hygromycin B. X63Ag8.653 myeloma cells (ATCC No. CRL-
1580; www.atcc.org), HeLa cells and HeLa cells ectopically
expressing the respective Flag-tagged versions of Lamin A
(hereafter termed HeLa Flag-Lamin A) - HeLa Flag-Lamin A
wt, HeLa Flag-Lamin A R453W, and HeLa Flag-Lamin A
R482W - were cultured at 37uC in an atmosphere of 7.5% CO2
(HeLa) or 5% CO2 (X63Ag8.653) in DMEM (Sigma) supple-
mented with 10% fetal bovine serum (FBS, Gibco), 1% Penicillin/
Streptomycin (Sigma), 2mM Glutamax (Gibco) and 1mM Na-
Pyruvate (Sigma). HeLa Flag-Lamin A cells were cultured in the
presence of 175 mg/ml Hygromycin B (Calbiochem). Hybridoma
clones were selected in hypoxanthine-aminopterin-thymidine
(HAT) medium consisting of DMEM, 10% FBS, 5% BM-
Condimed H1 Hybridoma Cloning Supplement (Roche),
100 U/ml Penicillin, 0.1 mg/ml Streptomycin, 2 mM Glutamax,
1 mM Na-Pyruvate, and HAT supplement (Gibco).
Primary human fibroblasts. Wild-type, R453W (G-8626),
and R482W (G-9956) primary human skin fibroblasts [24] were
provided by Manfred Wehnert and were cultured at 37uCi na n
atmosphere of 7.5% CO2 in DMEM supplemented with 10%
FBS, 100 U/ml Penicillin, 0.1 mg/ml Streptomycin, 2 mM
Glutamax and 1 mM Na-Pyruvate. All experiments were
performed with wild-type fibroblasts during passages 32–38,
R453W fibroblasts during passages 30–34, and R482W
fibroblasts during passages 28–32.
Western blotting/Dot blotting. Cells were lysed in pre-
heated Laemmli buffer to ensure complete solubilization of
nuclear lamina proteins. Proteins were separated by SDS-PAGE,
followed by blotting onto a nitrocellulose membrane (Whatman,
0.2 mm). For dot blots, 1 mg of peptides or recombinant proteins
were spotted onto a PVDF membrane (Millipore), and equal
spotted amounts were confirmed by Ponceau S staining. The
membranes were blocked with 3% non fat dry milk (NFDM) in
PBS-Tween 20 (0.05%) for 1 hour at RT and incubated with
primary antibody in 0.5% NFDM/PBS-Tween 20 o/n at 4uC.
Incubation with secondary peroxidase conjugated anti-mouse
antibody (AffiniPure Goat Anti Mouse IgG (Fcc fragment) specific
antibody, Jackson ImmunoResearch, 1:5000) was performed for 1
hour at RT, followed by incubation with Western Lightning ECL
solution (PerkinElmer) as suggested by the manufacturer. The
signals were detected by a Super HR-HA 30 film (Fuji). Lamin A
and C were detected with mouse monoclonal antibody, clone
4C11, which was raised against the wild-type Ig-fold domain.
Mature lamin A was detected with a mouse monoclonal antibody,
clone 4A4, which was raised against a C-terminal peptide of
mature lamin A. Commercially available antibodies were: anti
Prelamin A (1:500, C-20, Santa Cruz), anti Lamin A/C (1:1000,
N-18, Santa Cruz), anti Flag (1:10000, M2, Sigma,) and anti b-
actin (1:5000, clone AC-74, Sigma).
Immunofluorescence
Cells were seeded onto glass cover-slips, and cultured o/n in the
appropriate medium. The cover-slips were washed 2x with PBS
and fixed in 3,7% formaldehyde/PBS for 15 min, quenched with
50 mM NH4Cl/PBS for 10 min, permeabilized with 0.2% Triton
Table 1. Oligonucleotides.
MCS_fw 59-CTACGTAGCATGCATGTACAACGAAGCTTACATG-39
MCS_rev 59-TAAGCTTCGTTGTACATGCATGCTACGTAGGTAC-39
Ig-fold_fw 59-CACATTGGTACCTTCTCACAGCACGCACGC-39
Ig-fold_rev 59-GAAATTGTACATGCGCACCAGCTTGCGCATGG-39
478–487 R482W_fw 59-CTTGCTGACTTACTGGTTCCCACCAAAGTTCAT-39
478–487 R482W_rev 59-GTACATGAACTTTGGTGGGAACCAGTAAGTCAGCAAGGTAC-39
472–492 R482W_fw 59-CCAGAATGGAGATGATCCCTTGCTGACTTACTGGTTCCCACCAAAGTTCACCCTGAAGGCTGGGAT-39
472–492 R482W_rev 59-GTACATCCCAGCCTTCAGGGTGAACTTTGGTGGGAACCAGTAAGTCAGCAAGGGATCATCTCCATTCTGGGTAC-39
458_fw 59-CACATTGGTACCTCCAATGAGGACCAG-39
503_rev 59-GAAATTGTACATCCCAGCTCCTGCAGC-39
438_fw 59-CACATTGGTACCGGGCGCGTGGCCGTG-39
523_rev 59-GAAATTGTACATCCCGCAGCCCCAGGT-39
doi:10.1371/journal.pone.0010604.t001
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1 hour and then incubated with the primary antibody diluted in
0.2% gelatine/PBS for 2 hours. For staining with the anti R453W
antibody, permeabilization was carried out in the presence of
0.1% SDS. Commercially available primary antibodies included:
goat anti-LA/C (1:200; N-18, Santa Cruz) and anti Flag (1:1000;
M2, Sigma). Incubation with secondary antibodies, Alexa Fluor
594 goat anti-mouse IgG (H+L) (1:500, Molecular Probes), Alexa
Fluor 488 donkey anti-mouse (H+L) (1:500, Molecular Probes), or
donkey anti-goat IgG (H+L) Texas Red (1:200, Jackson Im-
munoResearch) was done for 1 hour. The DNA was counter-
stained with Hoechst 33342 and the cover-slips were mounted
with Vectashield (Vector Laboratories). All steps were performed
at RT. Pictures were taken with a Zeiss LSM 510 Meta confocal
microscope using the corresponding LSM 510 META software.
Relative fluorescence intensity profiles were determined using the
same software. For presentation, images were adjusted for
brightness and contrast.
Peptide/Ig-fold competition assay
For competition with peptide, the R453W antibody was diluted
in 0.5% NFDM/PBS-Tween 20 as appropriate for Western
blotting (1:100) and a fixed amount of antibody was incubated
with increasing amounts of the peptide (0,44pmol, 2,2pmol,
11pmol, 55pmol) o/n at 4uC. Nitrocellulose membranes were then
incubated for 2 hours at RT with the respective antibody-peptide
solutions, and subjected to Western blot detection as described
above. For competition with recombinant protein, fixed amounts
of His-HBcAg-Ig-fold fusion proteins (wt or R482W; 0,13nmol)
were incubated with decreasing amounts of R482W antibody
(38 ml, 3,8 ml, 0.38 ml of hybridoma supernatant) in 0.5% NFDM/
PBS-Tween 20 for 2 hours at RT. After the competition, all
antibody-HBcAg-Ig-fold solutions were then further diluted
appropriately in 0.5% NFDM/PBS-Tween 20 to give the same
antibody dilution (1:250) for Western blotting and used for
Western blot detection as described above.
Native cell lysates and immunoprecipitation
Cells were lysed in ice-cold cell lysis buffer (20 mM Tris pH 7.5,
150 mM NaCl, 1 mM EDTA, 1mM EGTA, 1% Triton X-100,
PMSF, Aprotinin, complete protease inhibitor cocktail (Roche))
for 5 min on ice, followed by sonication on ice (365 seconds).
Antibodies (anti R453W, anti R482W, anti lamin A/C 4C11)
were covalently cross-linked to protein A sepharose beads (GE
Healthcare). Immunoprecipitation was performed for 1 hour at
4uC (anti R482W and anti lamin A/C 4C11), or for 1 hour at RT
in the presence of 0.25% SDS (anti R453W). After washing, the
beads were boiled in Laemmli buffer and immunoprecipitated
proteins were separated by SDS-PAGE for subsequent detection
by Western blotting.
Sub-cellular fractionation
Fractionation was performed according to published protocols
[25,26]. Briefly, cells were resuspended in 1 ml Buffer F1 (20 mM
Tris pH 7.6, 50 mM b-Mercaptoethanol, 0.1 mM EDTA, 2 mM
MgCl2, Aprotinin, PMSF, complete protease inhibitor cocktail
(EDTA free)) per 5610
6 cells and incubated for 2 min at RT,
followed by incubation on ice for 10 min. NP-40 was added to a
final concentration of 1% (v/v) and the solution was homogenized
by repeated pipetting through a yellow Gilson tip. The nuclei were
pelleted by centrifugation at 600 g for 5 min at 4uC, separated
from the cytoplasmic fraction and washed 2x in Buffer F1 + 1%
NP-40 (v/v). Nuclei were resuspended in 500 ml hypotonic buffer
(10 mM HEPES pH 7.4, 10 mM NaCl, 5 mM MgCl2,1m M
EGTA, 1 mM DTT, 8.5% sucrose (w/v), PMSF, Aprotinin,
complete protease inhibitor cocktail (EDTA free)) per 10
7 nuclei.
For low salt extraction, NaCl was added to a final concentration of
50 mM. For high salt/detergent extraction, NaCl was added to a
final concentration of 200 mM and Triton X-100 to a final
concentration of 1% (v/v). The samples were incubated for
20 min on ice and subsequently centrifuged at 16000 g for 30 min
at 4uC. Soluble and insoluble fractions were boiled in Laemmli
buffer, and the proteins were separated by SDS-PAGE and
detected by Western blot analysis.
Materials will be sent out upon request to EO or SS.
Results
We sought to develop antibodies against two disease-linked
lamin A/C mutants, R453W and R482W, because of their
relatively frequent incidence and the gross change in the amino
acid side chain. To ensure a high chance of stimulating a mutant-
specific immune response, two complementary approaches of
antigen presentation were pursued: first, we used short synthetic
peptides of nine amino acids coupled to KLH with the respective
tryptophan residue in the center position (Figure 1A). Second, the
lamin A/C Ig-fold domain (aa 430–545) - either with the wild-type
sequence or containing the R453W or the R482W substitution -
was inserted into the hepatitis B virus capsid protein (HBcAg) that
lacks the C-terminal DNA/RNA-binding region (Figure 1D).
HBcAg is a very strong immunogen containing potent T helper
cell epitopes and the immunodominant c/e1 B cell epitope
surrounding amino acid 80 (Figure 1C) [27]. In addition, HBcAg
can also act as a T-cell independent antigen due to its ability to
form multimers, which allows the simultaneous cross-linking of
sufficient surface B-cell receptors to activate naive B-lymphocytes
without the help of T-lymphocytes [28]. It has been shown that a
strong and specific humoral immune response can be mounted
against heterologous proteins like the green fluorescence protein
(GFP) or the outer surface protein A (OspA) from Borrelia burgdorferi
when inserted into HBcAg at the c/e1 epitope [28,29]. We
reasoned that the compact structure of the lamin A/C Ig-fold
together with the fact, that the N- and C-termini of this domain
are in close spatial proximity (Figure 1B) [10,11], should allow the
expression of a recombinant fusion protein in bacteria, in which
the lamin A/C Ig-fold would adapt its native conformation and be
situated at the position of the highly immunogenic c/e1 B cell
epitope of the hepatitis antigen (Figure 1D). Interestingly, arginine
482 lies within a short stretch of amino acids, which have been
shown to represent a major surface epitope of lamin A [30]. We
therefore hypothesized that, although the Ig-fold comprises 116
amino acids and most likely contains a number of potential B cell
epitopes [31,32], at least the FPLD-associated R482W mutant
could represent a likely target when presented in the context of the
whole native Ig-fold domain.
Lamin A/C R453W antibody is specific for the EDMD-
causing point-mutant R453W
A monoclonal antibody was generated from a Balb/c mouse
immunized with the R453W-KLH peptide (aa 449–457) and its
specificity for the R453W point-mutant was examined by Western
blotting using lysates of HeLa cells as well as HeLa cells expressing
Flag-lamin A wt, Flag-lamin A R453W, or Flag-lamin A R482W,
respectively (Figure 2A, top panel). The R453W antibody
recognized specifically the Flag-lamin A R453W mutant, but did
not cross-react with Flag-lamin A wt or -R482W. The fact that
Flag-lamin A wt was not detected by the R453W antibody could
be due to the significantly lower expression levels of Flag-lamin A
Point Mutant Specific Antibody
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staining with a Flag-specific antibody (Figure 2A, second panel).
However, the R453W antibody did not detect any endogenous wt
lamin A or lamin C, which were detected using a monoclonal
lamin A/C antibody, clone 4C11 (Figure 2A, third panel). This
antibody had been raised against the wt lamin A/C Ig-fold and
recognizes the wt and mutant lamin A/C proteins, albeit the
R453W mutant to a lesser extent (Figure S1). Taken together,
these findings strongly suggested that the R453W antibody was
specifically recognizing the respective mutant form of lamin A.
The specificity of the antibody was further examined by a
peptide competition assay (Figure 2B). The peptide containing the
R453W substitution and the corresponding wild-type peptide were
tested for their ability to interfere with the binding of the R453W
antibody to Flag-lamin A R453W by pre-incubating the antibody
with increasing amounts of peptides followed by Western blotting.
Detection of the Flag-tagged lamin A R453W mutant was strongly
reduced by pre-incubation of the antibody with 2.2pmol of the
mutant R453W peptide, and completely abolished by pre-
incubation with 11pmol of the mutant peptide. In contrast,
55pmol (and even amounts of up to 1nmol, data not shown) of the
wild-type peptide could not interfere with detection of Flag-lamin
A R453W, indicating that the point-mutant specific antibody did
not have any detectable affinity for the wild-type peptide.
We next examined whether the R453W antibody would also
specifically detect the mutant protein in immunofluorescence
analysis (IF; Figure 2C). HeLa and HeLa Flag-lamin A-R453W
cells were seeded at a ratio of 3:1, and subsequently stained with
the indicated antibodies. The general lamin A/C antibody, 4C11,
stained all cells (lower panel). In contrast, a Flag-tag antibody
stained only a sub-population of cells (middle panel). Similarly, the
R453W antibody stained just approximately one quarter of all
cells (upper panel), suggesting that also by IF it was only detecting
the ectopic Flag-lamin A mutant.
Lamin A/C R482W antibody is specific for the FPLD-
causing point-mutant R482W
Substitutions of arginine 482 are responsible for 80% of FPLD
cases and 13% of all laminopathies. Thus, we sought to develop a
second point-mutant specific antibody against the lamin A/C
R482W mutant by immunizing mice with the respective KLH-
coupled peptide encompassing amino acids 478–486. Interesting-
Figure 2. R453W antibody is specific for the EDMD associated lamin A/C R453W point-mutant. (A) HeLa, HeLa Flag-Lamin A wt, HeLa
Flag-Lamin A R453W, and HeLa Flag-Lamin A R482W cell lysates were separated by 7.5% SDS-PAGE and analyzed by Western blotting with the mouse
monoclonal antibodies anti R453W (panel I), anti Flag M2 (panel II), anti Lamin A/C 4C11 (panel III), and b-actin (panel IV). (B) Peptide competition of
R453W antibody. Binding of R453W antibody to Flag-Lamin A R453W was competed with increasing amounts (0.44, 2.2, 11, and 55pmol) of mutant
‘‘R453W Peptide’’ (NH2-
449GKFVWLRNK
457-COOH) or wild-type ‘‘wt Peptide’’ (NH2-
449GKFVRLRNK
457-COOH).Competition efficiency was examined by
7.5% SDS-PAGE/Western blot analysis of HeLa Flag-Lamin A R453W cell lysates. Control antibodies were: anti R453W not subjected to competition,
anti Flag M2, anti Lamin A/C 4C11. (C) Immunofluorescence of a mixed population of HeLa and HeLa Flag-Lamin A R453W cells, seeded at a ratio of
3:1. Cell staining was performed with anti R453W (top panel), anti Flag M2 (middle panel), and anti Lamin A/C 4C11 (bottom panel). DNA was
counterstained with Hoechst 33342. Bar scale, 20 mm.
doi:10.1371/journal.pone.0010604.g002
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developed ‘‘general’’ antibodies against lamin A/C, but none
showed a mutant-specific immune response by Western blotting
(data not shown).
Therefore we applied an alternative way of antigen presenta-
tion, using a native, recombinant HBcAg Ig-fold R482W fusion
protein. By this approach, one would expect that the immunized
animals develop antibodies against numerous B-cell epitopes on
the surface of the Ig-fold [31,32]. Indeed, the polyclonal sera of
most of the immunized mice recognized endogenous lamin A/C
as well as ectopic Flag-lamin A R482W in HeLa cell lysates (data
not shown). While we were able to confirm the presence of
R482W mutant-specific antibodies within the polyclonal mixture
by means of fusing splenocytes from such animals with myeloma
cells and seeding the cell-hybrids at low density, none of the
mutant-specific antibody producing hybridoma clones was stable
(data not shown). However, one out of 8 mice immunized with the
HBcAg Ig-fold R482W fusion protein developed a polyclonal
immune response, which was predominantly detecting the lamin
A/C R482W mutant (data not shown), and a monoclonal
antibody was generated from this mouse.
We first tested the specificity of the R482W monoclonal
antibody by Western blotting using again lysates from HeLa,
HeLa Flag-lamin A wt, HeLa Flag-lamin A R453W, and HeLa
Flag-lamin A R482W cells. The R482W antibody specifically
detected Flag-lamin A R482W with no cross-reactivity to the other
two Flag-tagged lamin A proteins (Figure 3A, top panel; the Flag,
lamin A/C and b-actin blots in Figure 3A are identical to
Figure 2A). In addition, also endogenous lamin A and C were not
detected. We have to note, however, that when used under sub-
optimal conditions, e.g. large amounts of protein lysate paired with
high concentrations of antibody, the R482W antibody cross-
reacted very weakly with endogenous wild type lamin A/C,
indicating a very low but detectable affinity of the R482W
antibody for the wild-type proteins (data not shown).
Similar to the R453W antibody, we wanted to affirm the
specificity of the R482W antibody in a competition assay using
wild-type and mutant peptides corresponding to amino acids 478
to 486 of lamin A/C. However, we did not observe any
competition (data not shown) indicating that the R482W antibody
did not bind to such short peptides. Thus, a competition assay was
performed, in which the mutant R482W Ig-fold and the
Figure 3. R482W antibody is specific for the FPLD-associated lamin A/C R482W point-mutant. (A) 7.5% SDS-PAGE of HeLa, HeLa Flag-
Lamin A wt, HeLa Flag-Lamin A R453W, and HeLa Flag-Lamin A R482W cell lysates followed by Western blot analysis with the mouse monoclonal
antibodies anti R482W (panel I), anti Flag M2 (panel II), anti Lamin A/C 4C11 (panel III), and b-actin (panel IV). (B) Ig-fold competition of R482W
antibody. Binding of anti R482W to Flag-Lamin A R482W was competed with recombinant HBcAg protein containing either the wild-type Ig-fold, ‘‘Ig-
wt’’, or the mutant Ig-fold, ‘‘Ig-R482W’’, at increasing molar ratios. Competition efficiency was examined by 7.5% SDS-PAGE/Western blot analysis of
HeLa Flag-Lamin A R482W cell lysates. Control antibodies were: anti R482W not subjected to competition, anti Flag M2, anti Lamin A/C 4C11. (C)
Immunofluorescence of a mixed population of HeLa and HeLa Flag-Lamin A R482W cells, seeded at a ratio of 3:1. Cells were stained with anti R482W
(top panel), anti Flag M2 (middle panel), and anti Lamin A/C 4C11 (bottom panel). DNA was counterstained with Hoechst 33342. Bar scale, 20 mm.
doi:10.1371/journal.pone.0010604.g003
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conditions as HBcAg fusion proteins) were tested for their ability
to sequester the antibody and interfere with detection of Flag-
lamin A R482W by Western blot analysis (Figure 3B). Pre-
incubation at increasing ratios of mutant R482W Ig-fold to
antibody progressively reduced detection of Flag-lamin A R482W.
On the other hand, while the Western blot signal was generally
slightly weaker after incubation with the wild-type Ig-fold
compared to the mock treated antibody control, increasing ratios
of wild-type Ig-fold to antibody did not abolish detection of Flag-
lamin A R482W, suggesting that the HBcAg-Ig-fold wt could not
sequester the R482W-specific antibody. These findings further
highlighted the high specificity of the lamin A/C R482W antibody
for the mutant protein.
Finally, the usefulness of the antibody for immunofluorescence
studies was again tested using HeLa and HeLa Flag-lamin A
R482W cells that were seeded at a ratio of 3:1 and stained with the
indicated antibodies (Figure 3C). While the general anti-lamin A/
C antibody stained all cells, only sub-populations of cells were
stained by the Flag-tag antibody or the R482W antibody,
respectively, again strongly suggesting that the R482W antibody
was specifically recognizing only the ectopic mutant protein.
The R482W antibody recognizes a conformation-
dependent discontinuous epitope
The results of the competition experiments with the R482W
antibody indicated that the epitope of this antibody may comprise
either a linear continuous sequence that is longer than the 9-mer
peptide used for the competition experiment, or a discontinuous,
conformational epitope in the natively folded lamin A/C Ig-fold.
The R453W antibody, on the other hand, recognized a
continuous epitope as suggested by the efficient blocking of
antigen recognition by a linear 9-mer peptide containing the
R453W mutation. To further examine the binding abilities of the
two antibodies, we carried out a dot-blot assay with wild-type and
mutant peptides or entire Ig-fold domains (Figure 4A). Consistent
with the results of the competition experiments, the R482W
antibody specifically detected the R482W mutant only if displayed
in the Ig-fold, whereas the R453W antibody recognized the
mutant displayed in the peptide as well as in the Ig-fold. In order
to map the R482W epitope we examined the ability of the
antibody to detect by Western blot Ig-fold R482W fragments of
increasing size inserted into the HBcAg protein (Figure 4B).
Strikingly, the R482W antibody detected only the full-length
mutant Ig-fold suggesting that the presence of the whole Ig-fold
domain was required for recognition by the R482W antibody.
This finding strongly indicated that the R482W antibody
recognized a conformational, discontinuous or - less likely -
continuous epitope, because deletions of parts of the Ig-fold are
likely to disrupt the native folding of the polypeptide. This
conformation-dependency, however, also suggested that the lamin
Ig-fold had refolded, at least partially, on Western blot membranes
after SDS-PAGE.
Specific detection of lamin A/C mutant proteins in
primary patient skin fibroblasts
Since most laminopathy-associated LMNA mutations are
inherited as dominant traits, point-mutant specific antibodies
would allow for the first time to study in patient cells potential
alterations of the mutant protein, such as sub-cellular localization,
protein interactions, or post-translational modifications, a task, for
which so far no research tools have been available that could
distinguish the point-mutant from the wild-type protein. Hence,
we next examined whether the unique features of our novel
antibodies could also be employed to investigate by Western
blotting, immunofluorescence staining, and immunoprecipitation
the mutant forms of lamin A and lamin C in diseased primary
human cells. For these studies, skin fibroblasts from an EDMD
patient heterozygous for the R453W LMNA mutation, as well as
skin fibroblasts from an FPLD patient heterozygous for the
R482W LMNA mutation were used.
The R453W antibody detected lamin A and lamin C only in the
EDMD fibroblast lysate, whereas the R482W antibody recognized
lamin A and lamin C only in the lysate of FPLD fibroblasts
(Figure 5A, panel I and II). Similar to the results obtained in the
HeLa cell system, neither antibody cross-reacted with the other
mutant or detected the wild-type proteins in control skin
fibroblasts from a healthy donor.
Furthermore, both antibodies also displayed unique specificity
for the respective lamin A/C mutants by immunofluorescence.
The general lamin A/C antibody stained the nuclei in wild-type
control as well as EDMD and FPLD cells (Figure 5B+C, lower
panels). In contrast, cell staining with the mutant-specific
antibodies was only observed in the EDMD or the FPLD cells,
respectively (Figure 5B+C, upper panels), underlining the
Figure 4. R482W antibody recognizes a discontinuous epitope
in the lamin A/C Ig-fold. (A) Equal amounts of peptide pR482
(
472QNGDDPLLTYRFPPKFTLKAG
492), pW482 (
472QNGDDPLLTYWFP-
PKFTLKAG
492), pR453 (
449GKFVRLRNK
457), pW453 (
449GKFVWLRNK
457)
and equal amounts of recombinant HBcAg Ig-fold wt, HBcAg Ig-fold
R453W, and HBcAg Ig-fold R482W were spotted onto PVDF membranes.
Blots were incubated either with anti R482W antibody (upper left
panels) or with anti R453W antibody (upper right panels). Anti lamin A/
C (middle panels) and Ponceau S staining (bottom panels) confirmed
equal spotting of recombinant HBcAg Ig-fold proteins or peptides,
respectively. (B) 12.5% SDS-PAGE of bacterial lysates expressing His-
tagged HBcAg Ig-fold R482W fragments of increasing size followed by
Western blot analysis with R482W antibody (left panel). Equal amounts of
recombinant proteins were confirmed by incubation with anti-His
antibody (right panel). Numbers correspond to amino acids of lamin A/C.
doi:10.1371/journal.pone.0010604.g004
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R453W antibody in EDMD fibroblasts indicated that a fraction of
the lamin A/C R453W mutant might be partially aggregated in
the nucleoplasm, while the R482W antibody primarily stained the
nuclear envelope in FPLD fibroblasts. In agreement with earlier
reports [33,34], we observed a high percentage of FPLD patient
cells containing grossly mis-shaped nuclei with invaginations and/
or blebs, which were also apparent by staining with general lamin
A/C antibodies (data not shown) or Hoechst DNA staining (Figure
S2A). In contrast to one of these reports [33], however, we did not
detect any significant differences in prelamin A - or vice versa in
mature lamin A - levels between FPLD, wild-type or EDMD cells
(Figure S2B).
Finally, we also tested the potential of the two novel antibodies
to immunoprecipitate the respective mutant proteins. Indeed, both
antibodies specifically immunoprecipitated the mutant proteins
Figure 5. R453W and R482W antibodies recognize the respective disease causing mutant A-type lamins in primary patient
fibroblasts. (A) Western blot analysis of wild type, EDMD (R453W), and FPLD (R482W) primary human fibroblast lysates with anti R453W (panel I),
anti R482W (panel II), anti Lamin A/C 4C11 (panel III), and anti b-actin (panel IV). (B) Immunofluorescence of wild-type and EDMD primary human
fibroblasts. Cells were stained with anti R453W (top panels) and anti Lamin A/C 4C11 (bottom panels). The DNA was counterstained with Hoechst
33342. Bar scale, 20 mm. (C) Immunofluorescence of wild-type and FPLD primary human fibroblasts. Cells were stained with anti R482W (top panels)
and anti Lamin A/C 4C11 (bottom panels). The DNA was counterstained with Hoechst 33342. Bar scale, 20 mm. (D) Immunoprecipitation of wild-type
and mutant lamin A/C from wild-type, EDMD, and FPLD cell lysates. The precipitated proteins were separated by 7.5% SDS-PAGE and analyzed by
Western blotting with either the anti R453W or anti R482W antibody (top panels), or with anti Lamin A/C 4C11 (bottom panels).
doi:10.1371/journal.pone.0010604.g005
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A/C from wild-type cells (Figure 5D, top panels), again
highlighting the specificity of both antibodies.
The wild-type and R453W mutant protein localize
differently in EDMD fibroblasts
To further investigate in the primary human wild-type or
patient fibroblasts the subnuclear distribution of A-type lamins we
performed double cell stainings with a widely used goat polyclonal
antibody recognizing a Lamin A/C N-terminal epitope, N-18
(Santa Cruz) [35,36,37], in combination with 4C11, anti R453W,
or anti R482W (Figure 6A). While antibody 4C11 predominantly
stained the nuclear envelope in all cell types (Figure 6A, upper
panel and data not shown), antibody N-18 also recognized lamin
A/C in the nucleoplasm. The double stainings revealed very
prominent co-localizing foci in the nuclear interior of all three cell
types (Figure 6A, arrowheads). Serial optical sections along the z
axis showed, that these foci represented continuous structures
either ranging from one side of the nucleus to the other, or
penetrating from the nuclear envelope deep into the nuclear
interior (Figure 6, upright projections). Similar tubular structures
have been shown to consist of two membranes continuous with the
nuclear envelope and to be decorated on the nucleoplasmic side
with lamins [38]. Interestingly, EDMD patient cells contained a
significantly higher number of transnuclear tubules than the wild-
type cells (Figure 6B). While we also observed an increased
number of transnuclear tubules in FPLD cells, the difference to
wild-type cells was statistically not significant. In rare cases, we
even observed very wide channels with diameters of several mmi n
EDMD cells (Figure 6C), suggesting that nuclear reassembly might
be affected in these cells [38].
Close inspection of the intranuclear N-18- or R453W-specific
stainings in horizontal mid-plane sections of EDMD nuclei
revealed well-defined lamin foci of varying size (Figure 7A).
Several of these foci were co-stained by both antibodies and
represented mostly either transnuclear tubules or deep, narrow
invaginations of the nuclear envelope. However, the majority of
nucleoplasmic foci stained by the N-18 antibody did not colocalize
with those stained by the R453W mutant-specific antibody
(Figure 7A, enlarged details of nuclear interior). This finding
suggested a distinct intranuclear distribution of the R453W
mutant and the wild-type protein that could only be detected by
the novel R453W mutant-specific antibody but not the N-18
polyclonal antibody, which was hampered in the detection of the
intranuclear R453W mutant proteins. Finally, biochemical
subcellular fractionation experiments, testing for salt/detergent
resistant versus extractable lamin fractions, did not show any
significant differences in the solubility of lamin A and C in the
wild-type and EDMD primary cells (Figure 7B).
Discussion
Here we present two novel monoclonal antibodies specifically
detecting disease causing point mutants of A-type lamins, namely
the AD-EDMD associated lamin A/C R453W mutant and the
FPLD associated lamin A/C R482W mutant. While the R453W
specific antibody was raised against a short peptide, we were
unsuccessful in generating an R482W mutant specific antibody by
a similar approach. Rather, immunization with a fusion protein
consisting of the hepatitis B virus capsid protein, HBcAg, and the
lamin A/C Ig-fold R482W domain inserted at the highly
immunogenic viral c/e1 epitope resulted in the generation of the
R482W specific antibody. In addition, by the latter approach
using a HBcAg-Ig-fold wt fusion protein the 4C11 antibody was
generated, which recognizes an as yet undefined epitope within the
Ig-fold domain and detects lamin A/C wt, R453W, and R482W.
Because of its excellent features in Western blotting, immunoflu-
orescence, and immunoprecipiation, this antibody was used
throughout this study to detect endogenous A-type lamins.
Interestingly, immunization with the HBcAg-Ig-fold R453W
fusion protein did not result in the generation of a mutant-specific
immune response (data not shown). AD-EDMD associated
missense mutations in the LMNA gene are thought to result in
misfolding of the protein or the failure to assemble into lamin A
polymers [39], and Krimm et al. have shown that the substitution
of arginine 453 by tryptophan causes a dramatic reduction of the
denaturation temperature of the Ig-fold domain due to the loss of a
Figure 6. EDMD patient cells contain an increased number of
transnuclear tubules. (A) Immunofluorescence of wild-type (top
panel), EDMD (middle panel), and FPLD (bottom panel) primary human
fibroblasts. Cells were co-stained with anti Lamin A/C N-18 and anti
Lamin A/C 4C11, anti R453W, or anti R482W, respectively. Mid plane
sections, xz-projections (above), and yz-projections (right) of the nuclei
are shown. Arrowheads indicate transnuclear tubules through which
the respective projection planes cut. Bar scale, 10 mm. (B) Number of
transnuclear tubules per cell for wild-type, EDMD, and FPLD fibroblasts.
n=44 (wild-type), n=46 (EDMD), n=50 (FPLD). ** p,0.02; * p=0.13.
(C) Merged image of a mid plane section, xz-projection (above), and yz-
projection (right) of an EDMD nucleus. Bar scale, 10 mm.
doi:10.1371/journal.pone.0010604.g006
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Immunofluorescence of two EDMD nuclei. Cells were co-stained with anti Lamin A/C N-18 and anti R453W. Fluorescence intensity of the lamin
A/C staining by the two antibodies along the dashed lines in the magnified images of the nucleoplasm (4
th image in each row) and of the nuclear rim
(last image in each row) are shown above or below the respective images. Areas of magnification (3.5-fold) are indicated by white squares in the
merged images of each nucleus. Bar scale, 10 mm. (B) Cellular fractionation of wild-type and EDMD cells. Whole cell lysate (WC), cytoplasmic (C),
whole nuclear (N), low-salt soluble nuclear (LS), low-salt insoluble nuclear (LP), high-salt soluble nuclear (HS), and high-salt insoluble nuclear (HP)
fractions were separated by 7.5% SDS-PAGE and analyzed by Western blotting with the indicated antibodies.
doi:10.1371/journal.pone.0010604.g007
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observed a reduced solubility of the R453W mutant fusion protein
compared to the HBcAg Ig-fold wt and R482W, suggesting
improper folding of the recombinant protein due to the instability
of the R453W mutant Ig-fold. We also note, that lamin A/C
R453W could only be immunoprecipitated with the R453W
specific antibody in the presence of 0.25% SDS (Figure 5D),
supporting the idea of a destabilized structure of the mutant. Such
a treatment most likely results in a partial denaturation of the
mutant lamin A/C, thereby possibly making the epitope
encompassing W453 accessible for the anti-peptide R453W
antibody. However, fractionation assays of EDMD cells did not
reveal significant differences in the solubility of the wild-type and
the mutant lamin A/C proteins.
In the case of the R482W lamin A/C mutant, we were unable
to obtain an R482W mutant specific immune response against the
full-length protein when short peptides were used for immuniza-
tions (data not shown). However, when we used the entire Ig-fold
domain harboring the R482W mutation for the immunizations,
we readily obtained a R482W mutant specific immune response
and could generate a R482W monoclonal antibody suggesting that
the antigenicity of the R482W epitope depended on the
conformational context of the Ig-fold that evidently could not be
mimicked by a short linear peptide. Consistent with this, peptides
(either 9 or 21 amino acids long) were neither detected by the
R482W antibody nor could they impair binding of the antibody to
Flag-lamin A R482W, indicating that, while W482 must be part of
the functional epitope, the antibody was most likely recognizing a
discontinuous epitope in a conformation dependent manner.
Recently, the structure of the lamin A/C R482W mutant has been
shown to be almost identical to that of the wild-type protein [40].
Thus, the R482W antibody does not differentiate between the
wild-type and the mutant protein due to differences in their
conformation, but rather specifically recognizes the amino acid
side chain of W482, which has been shown to be solvent exposed
on the protein surface.
Recently, several groups have reported the generation of
specific antibodies against disease relevant point mutant proteins,
namely glial fibrillary acidic protein R416W, epidermal growth
factor receptor L858R, and isocitrate dehydrogenase R132H,
respectively [41,42,43,44]. In these studies, antibodies were raised
against short peptides, which combine the advantages of easy and
fast fabrication with the potential to design highly target-oriented
antigens. However, most, if not all, antibodies recognize
discontinuous epitopes, of which linear peptides represent only
parts of the binding interface between antigen and antibody [31].
In perfect agreement with this notion, our findings show that - as
for any protein - synthetic peptides representing short stretches of
mutant proteins may be of very limited use, if a mutation affects a
residue, which even if surface exposed is located at a structural
position within the protein, which does not allow to be remodeled
by a short linear amino acid chain that displays random
structures not present in the full length protein [45]. As an
alternative approach, the display of such residues in the context
of a complete protein or a defined protein domain may lead to
the desired immune response. Furthermore, even though we
failed to obtain a mutant-specific immune response for the
HBcAg Ig-fold R453W fusion protein, it is conceivable that for
other proteins, where a certain mutation leads to gross but stable
alterations in the three-dimensional structure of the protein, the
immunization with the respective mutant protein or protein
domain could also be beneficial for obtaining antibodies specific
for the mutant conformation but not necessarily the mutated
amino acid.
Several data presented here are in agreement with the idea that
the R482W antibody binds specifically to lamin A/C R482W, yet
only in a conformation-dependent manner when the whole Ig-fold
domain is present (Figure 3B and Figure 4). However, since this
antibody also detected specifically the mutant protein in the
immunoblot analysis, these findings would suggest that after
denaturing SDS-PAGE some proteins or protein domains can
refold into their native conformation, thereby contradicting the
general view of proteins being captured in a denatured state on a
Western blotting membrane. It will be interesting to see whether
this is a lamin A/C specific property, possibly because the Ig-fold
adapts an unusually stable conformation. Indeed, the CD analysis
of the Ig-fold reveals a melting temperature of 62uC, which is well
above the melting temperature of most proteins and indicates a
very stable structure [11]. Experiments are currently under way to
further investigate this phenomenon.
The antibodies presented and characterized in this study open
up completely new avenues to investigate the molecular mecha-
nisms of two laminopathies, AD-EDMD and FPLD, in patient
cells and tissues. So far the properties of disease-causing mutant A-
type lamins were studied by the ectopic expression of GFP- or
epitope-tagged proteins in the context of a variety of lamin A/C
wild type cells, leading to conflicting results about a possible
mislocalization of the two lamin A mutants [22,34,46,47,48]. By
transient transfection of C2C12 cells with Flag-tagged lamin A
mutants, O ¨ stlund et al. found that a sub-set of mutants, including
several AD-EDMD-linked mutants, was dramatically mislocalized
in many cells, but that all AD-EDMD mutants containing a
mutation within the Ig-fold, and in particular the R453W mutant,
showed no localization abnormalities. Likewise, localization of the
R482W mutant was essentially indistinguishable from that of wild-
type lamin A [22]. In contrast, Broers and colleagues found
differences in the sub-nuclear localization of both, the R453W and
the R482W lamin A and lamin C mutants compared to the wild
type proteins in CHO-K1 cells stably transfected with GFP-lamin
A or C fusion constructs [47]. Using GFP-tagged lamin, Wiesel et
al. have also shown recently that the C. elegans equivalent of the
human R453W mutant, Ce-lamin R460W, accumulates in
nuclear aggregates [48]. While these studies revealed several
interesting features of mutant Ce-lamins that may be similar to
human lamin A mutants, and some of the cellular phenotypes
resembled those seen in some patient cells [34], these results may
not provide the whole picture. For instance, Ce-lamin is a B-type
lamin and the only lamin expressed in worms, while mutant
human lamins are A-type lamins and their localization may be
affected by human B-type lamins and by lamin A/C binding
proteins missing in C. elegans. Also, the fact, that in some studies
immortalized rodent cell lines were used for the ectopic expression
of mutant lamins, may have impacted on some of their disease-
relevant properties. For instance, while most laminopathies are
inherited as dominant traits in humans, pathological phenotypes
due to amino acid substitutions become apparent in mouse models
only under homozygous conditions, thereby highlighting consid-
erable differences between humans and mice [21]. Furthermore,
even though the localization of wild-type lamin A/C fused to GFP
appeared normal, the GFP-tag might influence lamin properties
and thus laminopathy-associated functions of mutant lamins.
Finally, by changing the overall amount of A-type lamins by the
additional expression of a tagged lamin A/C protein, mutant or
wild-type, may also have an impact on lamin A/C properties in a
cell. In a first attempt to investigate the properties of mutant
lamins in primary patient cells using our novel antibodies, we
examined their subnuclear distribution by confocal immunofluo-
rescence microscopy. In EDMD fibroblasts, we found distinct
Point Mutant Specific Antibody
PLoS ONE | www.plosone.org 12 May 2010 | Volume 5 | Issue 5 | e10604lamin A/C foci in the nuclear interior that were detected either by
the R453W-specific antibody or a general lamin A/C antibody. In
contrast, the lamin A/C and R453W stainings showed near
perfect colocalization at the nuclear envelope. It is therefore
conceivable that antibody N-18 did not detect a sub-set of
R453W-specific intranuclear foci because the epitope of the N-18
antibody in the lamin A/C N-terminus may be inaccessible in
these structures. Hence, the R453W mutant lamin seems to exist
in at least two different protein pools: one pool at the nuclear
lamina and in transnuclear tubular extensions of the nuclear
envelope, which is also detectable by antibody N-18; and a second
pool in nucleoplasmic foci not co-stained by antibody N-18. The
specific consequences of this unique R453W-specific pool remain
unclear. It has been shown recently, that A- and B-type lamins
form separate but interconnected meshworks and microdomains,
which interact with different types of chromatin [37]. Thus, one
could speculate that mutant lamin aggregates might affect
chromatin organization. Interestingly, altered epigenetic chroma-
tin modifications have been found in EDMD mouse models as well
as patient muscles [49]. The two antibodies described here
represent a starting point to study not only potential abnormalities
in the sub-nuclear localization of lamin A/C R453W and R482W,
but their excellent features in immunoblotting and immunopre-
cipitation assays will also allow to study changes in the post-
translational modification status, protein stability and expression
levels, as well as the interacting proteome of the mutant proteins.
We propose that the generation of similar mutant-specific
antibodies will provide a way to study new aspects of many
hereditary or acquired somatic diseases in primary human cells,
which up to now have escaped direct experimental analysis.
Supporting Information
Figure S1 Anti lamin A/C, clone 4C11, recognizes wt, R453W,
and R482W Ig-folds. 12.5% SDS-PAGE/Western blot analysis of
Ni-agarose purified recombinant His-tagged HBcAg fusion
proteins with anti His (left panel) or anti lamin A/C, clone
4C11 (right panel).
Found at: doi:10.1371/journal.pone.0010604.s001 (0.19 MB TIF)
Figure S2 Increased number of dysmorphic nuclei in FPLD
fibroblasts. (A) Representative examples of dysmorphic nuclei
found in FPLD cells. Cells were stained with anti R482W and
DNA was counterstained with Hoechst 33342. Bar scale, 10 mm.
The percentage of dysmorphic nuclei for wild-type (p36), EDMD
(p34), and FPLD (p32) cells is displayed in the diagram. n=100 for
each cell type (B) SDS-PAGE/Western blot analysis of wild-type,
EDMD, and FPLD fibroblast lysates at the same passage numbers
as in (A) with anti Prelamin A (top panel), anti mature Lamin A
4A4 (middle panel), and anti Lamin A/C 4C11. A lysate of 16
hours FTI-277 treated T98G cells served as a positive control for
Prelamin A.
Found at: doi:10.1371/journal.pone.0010604.s002 (0.34 MB TIF)
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